MyFinsight
Home
Blog
About
Contact
Download
Download image
Maturities and sales of
investments
$1,201,284K
Proceeds from issuance of
common stock under espp
$2,797K
Proceeds from exercise of
stock options
$1,349K
Proceeds from sale of
equipment
$253K
Net cash provided by
investing activities
$310,371K
Net cash provided by
financing activities
$3,785K
Canceled cashflow
$891,166K
Canceled cashflow
$361K
Net (decrease)
increase in cash, cash...
-$77,625K
Canceled cashflow
$314,156K
Stock-based compensation
$49,072K
Depreciation and
amortization
$11,680K
Change in estimated
fair value of...
$11,490K
Amortization of premiums
(accretion of discounts) on...
-$9,474K
Accounts payable
$4,997K
Noncash lease expense
$4,980K
Prepaid expenses and
other current assets
-$2,075K
Non-cash restructuring,
long-lived assets...
$654K
Other non-cash items,
net
$172K
Purchases of investments
$886,334K
Purchases of long-lived
assets
$4,832K
Other financing
activities
-$361K
Net cash used in
operating activities
-$391,781K
Canceled cashflow
$94,594K
Net loss
-$437,987K
Payment of contingent
consideration in excess of...
-$17,140K
Other assets
$12,642K
Accrued liabilities and
other long-term...
-$9,509K
Operating lease
liabilities
-$7,368K
Change in fair value of
equity investments
-$1,729K
Back
Back
Cash Flow
source: myfinsight.com
Vir Biotechnology, Inc. (VIR)
Vir Biotechnology, Inc. (VIR)